skip to main content
Idioma:
Mostrar Somente
Refinado por: idioma: Chinês remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial
CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial

Shi, Yuankai ; Li, Jin ; Xu, Jianming ; Sun, Yan ; Wang, Liwei ; Cheng, Ying ; Liu, Wei ; Sun, Guoping ; Chen, Yigui ; Bai, Li ; Zhang, Yiping ; He, Xiaohui ; Luo, Yi ; Wang, Zhehai ; Liu, Yunpeng ; Yao, Qiang ; Li, Yuhong ; Qin, Shukui ; Hu, Xiaohua ; Bi, Feng ; Zheng, Rongsheng ; Ouyang, Xuenong

Cancer communications (London, England), 2019-05, Vol.39 (1), p.1-13 [Periódico revisado por pares]

London: BioMed Central

Texto completo disponível

Citações Citado por
2
Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer
Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer

CHENG Jianping ; ZHAO Xiaolin ; LI Zhen ; YANG Mengyuan ; CAO Shichang ; YU Jiufei

Zhongliu fangzhi yanjiu, 2020-07, Vol.47 (7), p.542-546 [Periódico revisado por pares]

Magazine House of Cancer Research on Prevention and Treatment

Texto completo disponível

Citações Citado por
3
Molecular mechanism of resveratrol combined with irinotecan in treatment of colorectal cancer
Molecular mechanism of resveratrol combined with irinotecan in treatment of colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Molecular mechanism of resveratrol combined with irinotecan in treatment of colorectal cancer

Li, Fang ; Yan, Rui-Yang ; Li, Kai-Yang ; Wang, Jue ; Wang, Li ; Shen, Hui ; Han, Cai-Li ; Liu, Min

Zhongguo zhongyao zazhi, 2023-04, Vol.48 (8), p.2212-2221 [Periódico revisado por pares]

China

Texto completo disponível

Citações Citado por
4
The efficacy and safety of modified FOLFIRINOX as first‐line chemotherapy for Chinese patients with metastatic pancreatic cancer
The efficacy and safety of modified FOLFIRINOX as first‐line chemotherapy for Chinese patients with metastatic pancreatic cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

The efficacy and safety of modified FOLFIRINOX as first‐line chemotherapy for Chinese patients with metastatic pancreatic cancer

Wang, Zhi‐Qiang ; Zhang, Fei ; Deng, Ting ; Zhang, Le ; Feng, Fen ; Wang, Feng‐Hua ; Wang, Wei ; Wang, De‐Shen ; Luo, Hui‐Yan ; Xu, Rui‐Hua ; Ba, Yi ; Li, Yu‐Hong

Cancer communications (London, England), 2019-05, Vol.39 (1), p.1-8 [Periódico revisado por pares]

London: BioMed Central

Texto completo disponível

Citações Citado por
5
Irinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trial
Irinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Irinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trial

Huang, Jing ; Xu, Binghe ; Liu, Ying ; Huang, Junxing ; Lu, Ping ; Ba, Yi ; Wu, Lin ; Bai, Yuxian ; Zhang, Shu ; Feng, Jifeng ; Cheng, Ying ; Li, Jie ; Wen, Lu ; Yuan, Xianglin ; Ma, Changwu ; Hu, Chunhong ; Fan, Qingxia ; Wang, Xi

Cancer communications (London, England), 2019-04, Vol.39 (1), p.1-10 [Periódico revisado por pares]

London: BioMed Central

Texto completo disponível

Citações Citado por
6
Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer
Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer

Xing, He ; Zhang, Jie ; Ge, Fengjuan ; Yu, Xinhang ; Bian, Huimin ; Zhang, Fuliang ; Fang, Jian

Zhongguo fei ai za zhi, 2021-03, Vol.24 (3), p.167-172 [Periódico revisado por pares]

China: Chinese Anti-Cancer Association Chinese Antituberculosis Association

Texto completo disponível

Citações Citado por
7
Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in Firstline Treatment of Metastatic Left-side Colon Cancer
Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in Firstline Treatment of Metastatic Left-side Colon Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in Firstline Treatment of Metastatic Left-side Colon Cancer

Cheng, Jianping ; Zhao, Xiaolin ; Li, Zhen ; Yang, Mengyuan ; Cao, Shichang ; Yu, Jiufei

Zhongliu fangzhi yanjiu, 2020-07, Vol.47 (7), p.542 [Periódico revisado por pares]

Tianjin: China Anti-Cancer Association

Texto completo disponível

Citações Citado por
8
Clinical Observation of Raltitrexed-based Regimen for Advanced Primary Liver Carcinoma
Clinical Observation of Raltitrexed-based Regimen for Advanced Primary Liver Carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Clinical Observation of Raltitrexed-based Regimen for Advanced Primary Liver Carcinoma

Ke, Wen ; Hua, Haiqing ; Qin, Shukui ; Qu, Wenshu ; Wang, Feng

Zhongliu fangzhi yanjiu, 2017-04, Vol.44 (4), p.281 [Periódico revisado por pares]

Tianjin: China Anti-Cancer Association

Texto completo disponível

Citações Citado por
9
Effect of basic fibroblast growth factor antibody combined with irinotecan on proliferation and apoptosis of small cell lung cancer H223 cells in vitro
Effect of basic fibroblast growth factor antibody combined with irinotecan on proliferation and apoptosis of small cell lung cancer H223 cells in vitro
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of basic fibroblast growth factor antibody combined with irinotecan on proliferation and apoptosis of small cell lung cancer H223 cells in vitro

Liao, Xiang-Hui ; Xu, Meng ; Xiang, Jun-Jian

Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2017-11, Vol.37 (11), p.1535-1539

China

Texto completo disponível

Citações Citado por
10
Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review.
Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review.
Material Type:
Artigo 		Adicionar ao Meu Espaço

Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review.

Yao, Nan ; Jiang, Lei ; Yang, Kehu ; Ye, Yancheng ; Mi, Denghai ; Min, Guangtao

Zhongguo fei ai za zhi, 2009-08, Vol.12 (8), p.884-888 [Periódico revisado por pares]

China: Chinese Anti-Cancer Association; Chinese Antituberculosis Association

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (12)

Data de Publicação 

De até
Refinar
  1. Antes de2009  (1)
  2. 2009Até2012  (3)
  3. 2013Até2016  (1)
  4. 2017Até2019  (6)
  5. Após 2019  (5)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.